Pfizer is a big company that makes medicines. It used to have a part of another company called Haleon. Haleon makes toothpaste and painkillers. Pfizer decided to sell its part of Haleon to other people for a lot of money. Now Pfizer has less control over Haleon, but they still own a part of it. Read from source...

The key takeaways from the article are:

1. Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding from 22.6% to 15%.
2. The transaction occurred on Monday, cutting Pfizer's shareholding from 22.6% to 15%.
3. Pfizer remains Haleon's largest shareholder despite the sale.
4. The divestment comes on the heels of Pfizer's recent challenges.
5. The sale of shares is priced at a 3.3% discount to Haleon's last closing price.
6. Pfizer had initially planned to sell about 540 million shares but increased this to 640 million due to strong demand.
7. Haleon confirmed it will repurchase approximately 60.5 million of its shares from Pfizer for 230 million pounds ($307.4 million).

None of these key takeaways, however, provide any evidence to support the author's conclusion that Pfizer's divestment will lead to a loss of 5% of its revenue. Additionally, the author provides no evidence to support his claim that Pfizer's stock is poised for a massive fall, despite the fact that it has declined by 2.66% year-to-date.

Moreover, the author's claims about the safety and efficacy of Oxbryta are not supported by any evidence. Instead, the author relies on emotional language and vague claims about "severe complications and deaths" without providing any specific details.

The author also repeatedly refers to Pfizer as a "pharma giant," which is a misleading and inaccurate characterization of the company. While Pfizer is a large and successful pharmaceutical company, it is not the only one, nor is it the largest.

Overall, the article suffers from a lack of evidence, biases, and inconsistencies, making it difficult to take the author's claims seriously.

Neutral

The article is mostly neutral.

A quick glance at the key points of the article can be seen below:

Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon

1. Pfizer Inc. PFE has divested a $3.3 billion stake in Haleon HLN, reducing its holding in the British consumer healthcare company.
2. The transaction occurred on Monday, cutting Pfizer’s shareholding from 22.6% to 15%. The shares were sold at 380 pence each, a 3.3% discount to Haleon’s last closing price.
3. Haleon, known for products like Sensodyne toothpaste and Panadol painkillers, saw its shares drop 1.2% to 388 pence in Tuesday morning trade. Despite the sale, Pfizer remains Haleon’s largest shareholder.
4. The U.S. drug giant had initially planned to sell about 540 million shares but increased this to 640 million due to strong demand, a book-runner on the deal stated. Haleon confirmed it will repurchase approximately 60.5 million of its shares from Pfizer for 230 million pounds ($307.4 million).
5. Pfizer Inc. stock closed at $28.94 on Monday, down 0.52% for the day, and is currently trading at $29.01 in pre-market, reflecting a slight gain of 0.24%. Year-to-date, Pfizer’s stock has declined by 2.66%.
6. Meanwhile, Haleon PLC – ADR finished at $10.58, down 0.84% on the same day, with a pre-market price up by 0.19%. The stock has performed well this year, rising by 28.55%, according to data from Benzinga Pro.

The article covers the divestment of a $3.3 billion stake by Pfizer Inc. in Haleon, the British consumer healthcare company. The transaction resulted in a reduction of Pfizer’s holding in Haleon from 22.6% to 15%. Haleon is known for products such as Sensodyne toothpaste and Panadol painkillers. Despite the sale, Pfizer remains Haleon's largest shareholder. The U.S. drug giant initially planned to sell about 540 million shares, but increased this to 640 million due to strong demand. Haleon confirmed it will repurchase approximately

ANALYTIC INSIGHT

### LIMITEUR:
Investment is a risk and you should never invest more than you can afford to lose. Always conduct your own research and consider your personal financial situation before making any trading or investing decisions.

### FINALMENT:
The information provided by Benzinga does not constitute financial advice. Please consult a financial advisor or other professional for guidance before making any financial decisions.

### IMPÔRTANT:
While the recommendations and analysis are carefully reviewed, Benzinga does not assume any responsibility for potential losses as a result of following them. Please consult your financial advisor before making any investment decisions.

### POLITIQUE DE CONFIDENTIALITÉ:
En continuant à utiliser ce site, vous acceptez notre utilisation des cookies. Voir notre Politique de confidentialité et de cookies pour plus d'informations.

### FAIRE UN DON:
Benzinga is a leading provider of financial news and analysis, offering comprehensive market coverage and real-time insights to inform your trading and investing decisions. By donating to Benzinga, you help us maintain our independence, conduct thorough research, and deliver accurate information to the public.

### ESPACE DES ANNONCEURS:
Benzinga est la source d'information financière de premier plan pour les commerçants et les investisseurs. Atteignez votre public cible avec notre large gamme de solutions publicitaires et présentez votre entreprise aux millions de personnes qui lisent Benzinga chaque mois. Contactez-nous dès aujourd'hui pour discuter de vos besoins publicitaires et obtenir un devis.

### SÉCURITÉ:
Benzinga priorise la sécurité et le respect de la vie privée de ses utilisateurs. Nous utilisons des cookies pour améliorer votre expérience de navigation sur notre site. En continuant à utiliser ce site, vous acceptez notre utilisation des cookies. Voir notre Politique de confidentialité et de cookies pour plus d'informations.

### ÉVÈNEMENTS:
Marketfy est un programme d'événements en direct qui vous offre l'accès à des experts du marché et à des professionnels de l'investissement. Assistez à des webinaires en direct, regardez des vidéos à la demande et profitez d'un accès exclusif aux conseils et aux analyses des meilleurs experts du secteur. Inscrivez-vous dès maintenant et restez informé des dernières tendances et opportun